Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.008 | 0.29 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0049 | 0.1436 | 0.1436 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Echinococcus multilocularis | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Treponema pallidum | flavodoxin | 0.003 | 0.0536 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0071 | 0.2465 | 0.8499 |
Echinococcus granulosus | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0227 | 1 | 1 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.003 | 0.0536 | 0.1849 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.003 | 0.0536 | 0.1849 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.008 | 0.29 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.003 | 0.0536 | 0.1849 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.008 | 0.29 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.008 | 0.29 | 1 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0536 | 0.1849 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Brugia malayi | flavodoxin family protein | 0.008 | 0.29 | 0.29 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0049 | 0.1436 | 0.4951 |
Schistosoma mansoni | diflavin oxidoreductase | 0.004 | 0.0972 | 0.335 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.004 | 0.0972 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.008 | 0.29 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.008 | 0.29 | 0.29 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0066 | 0.2242 | 0.2242 |
Echinococcus granulosus | methionine synthase reductase | 0.0049 | 0.1436 | 0.4951 |
Loa Loa (eye worm) | hypothetical protein | 0.0066 | 0.2242 | 0.2242 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Chlamydia trachomatis | sulfite reductase | 0.0049 | 0.1436 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.004 | 0.0972 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0071 | 0.2465 | 0.8499 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0066 | 0.2242 | 0.7729 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.008 | 0.29 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.008 | 0.29 | 1 |
Leishmania major | p450 reductase, putative | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.008 | 0.29 | 0.29 |
Giardia lamblia | Hypothetical protein | 0.0071 | 0.2465 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.008 | 0.29 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0066 | 0.2242 | 0.7729 |
Brugia malayi | flavodoxin family protein | 0.003 | 0.0536 | 0.0536 |
Trichomonas vaginalis | sulfite reductase, putative | 0.008 | 0.29 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0071 | 0.2465 | 0.8159 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0066 | 0.2242 | 0.2242 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.008 | 0.29 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0049 | 0.1436 | 0.1436 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0071 | 0.2465 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.003 | 0.0536 | 0.1849 |
Loa Loa (eye worm) | flavodoxin family protein | 0.003 | 0.0536 | 0.0536 |
Trypanosoma cruzi | p450 reductase, putative | 0.008 | 0.29 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0066 | 0.2242 | 0.2242 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.008 | 0.29 | 0.29 |
Echinococcus granulosus | carboxylesterase 5A | 0.0066 | 0.2242 | 0.7729 |
Brugia malayi | Carboxylesterase family protein | 0.0066 | 0.2242 | 0.2242 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0066 | 0.2242 | 0.2242 |
Schistosoma mansoni | cytochrome P450 reductase | 0.008 | 0.29 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.004 | 0.1001 | 0.345 |
Echinococcus multilocularis | methionine synthase reductase | 0.0049 | 0.1436 | 0.4951 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.